Cincinnati (Blue Ash), Ohio • Velocity Clinical Research
Phone: (513) 769-2767
Metabolic dysfunction-associated steatohepatitis (MASH) is the more serious form of metabolic (dysfunction) associated fatty liver disease (MAFLD) which causes the liver to swell and become damaged. Not all patients with steatosis will progress to MASH and there are currently no clear criteria to identify these patients. There are currently no approved medications for the treatment of MASH.
Velocity is enrolling people with the following risk factors for MASH for a clinical trial: known fatty liver, known diagnosis of MASH, high blood pressure, high triglycerides, overweight, type 2 diabetes.
For more information, complete the form on this page. After you submit your information, a Velocity enrollment specialist will call you to talk about the study. There is no obligation to participate — you can decide if the study is right for you.
©2023 Velocity Clinical Research | All Rights Reserved | Privacy Policy